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Abstract
Background: Endovascular treatment options for the superficial femoral artery are evolving rapidly. For long
lesions, the venous femoropopliteal bypass considered to be superior above the prosthetic bypass. An endoluminal
bypass, however, may provide equal patency rates compared to the prosthetic above knee bypass. The
introduction of heparin-bonded endografts may further improve patency rates. The SUrgical versus PERcutaneous
Bypass (SuperB) study is designed to assess whether a heparin-bonded endoluminal bypass provides equal patency
rates compared to the venous bypass and to prove that it is associated with improved quality of life, related to a
decreased complication rate, or not.
Methods/design: Two-hundred-twenty-two patients with peripheral arterial occlusive disease, category 3-6
according to Rutherford, will be randomized in two treatment arms; 1. the surgical femoro-popliteal bypass, venous
whenever possible, and 2. the heparin-bonded endoluminal bypass. The power analysis was based on a non-
inferiority principle, with an effect size of 90% and 10% margins (alpha 5%, power 80%). Patients will be recruited
from 5 teaching hospitals in the Netherlands during a 2-year period. The primary endpoint is primary patency and
quality of life evaluated by the RAND-36 questionnaire and the Walking Impairment Questionnaire. Secondary
endpoints include secondary patency, freedom-from-TLR and complications.
Discussion: The SuperB trial is a multicentre randomized controlled trial designed to show non-inferiority in
patency rates of the heparin-bonded endograft compared to the surgical bypass for treatment of long SFA lesions,
and to prove a better quality of life using the heparin bonded-endograft compared to surgically treatment, related
to a reduction in complications.
Trial Registration: Clinicaltrials: NCT01220245
Keywords: superficial femoral artery, femoro-popliteal bypass, endoluminal, stentgraft, peripheral arterial occlusive
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Background
In the treatment of long lesions of the superficial
femoral artery (SFA) the surgical venous bypass is con-
sidered the gold standard [1]. Bypass surgery, however,
is associated with complications and a prolonged hospi-
tal length of stay. Endovascular techniques have
advanced and provided new treatment options for per-
ipheral vascular disease, but may also induce complica-
tions as shown in the Basil trial [2]. Last few years
evidence has been accumulating that the treatment of
long lesions with (covered) stents may provide accepta-
ble short- and midterm primary patency rates, as sum-
marized in several recent reviews [3-7].
Randomized trials have shown that 1-year patency
rates of self-expanding nitinol metal stents vary between
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improvements in stent design and introducer sizes, one
of the major issues limiting patency is in-stent re-steno-
sis. It was recently demonstrated that with the use of
covered stents, re-stenosis is reduced to edge stenosis
only [8]. The efficacy of an ePTFE-covered nitinol stent
(Viabahn, W.L. Gore, Flagstaff, AZ, USA) in treating
chronic SFA long lesions, of over 8 cm length, is cur-
rently being compared to bare nitinol stents in a multi-
centre randomized controlled trial (VIBRANT trial).
The study hypothesis is that the use of ePTFE-covered
nitinol stents will result in greater mid-term (24
months) and long-term (36 months) patency. Although
interim analysis has shown no significant differences at
one-year, final results have to be awaited. Recently, the
4-year’s results of a randomized trial have been pub-
lished comparing an ePTFE-covered nitinol stent with
the above-knee ePTFE femoropopliteal bypass [9]. The
1-year and 2-year patency rates were 73% and 74%, and
63% and 64%, respectively [10,11] At 4-years of follow-
up, the primary patency rates were 59% and 58%,
respectively and limb salvage rates were also compar-
able. When compared to a prosthetic bypass, however
the venous bypass has better patency rates, with 1-year
and 4-year primary patency rates of 87% and 70%,
respectively. There are patient groups with long lesions
of the SFA, including patients with severe co-morbid-
ities, who might benefit from a less invasive treatment
strategy. The risk of wound complications, limb edema,
loss of the great saphenous vein, and cardiac complica-
tions may have to be taken into account when deciding
to treat surgically or endovascularly.
Heparin-bonded prosthetic bypass grafts have shown
improved patency rates in animal models and non-ran-
domized clinical trials [12-14]. Recently, the heparin-
bonding technology has been integrated within the Via-
bahn stentgraft. Using this technique results may further
improve to the level of the current gold standard; the
venous femoropopliteal bypass. Advantages of the endo-
luminal technique would be related to its minimal inva-
sive character: less pain, earlier recovery and less early
complications. To date, no studies have been performed
to compare the use of heparin-bonded stent grafts for
the treatment of long lesions of the SFA. The current
study has been designed to compare the use of heparin-
bonded stent grafts for the treatment of long lesions of
the SFA to the venous surgical femoropopliteal bypass
in a multicentre randomized controlled trial.
Methods and design
Study design
The design of the study is a multicentre prospective ran-
domized controlled trial comparing the patency of the
heparin-bonded endograft to the venous surgical bypass.
Endpoints are primary patency after 1, 2 and 5 years,
complications and quality of life.
Study objectives
The aim of the study is to demonstrate that the heparin-
bonded endograft provides equal patency rates com-
pared to the venous surgical femoro-popliteal bypass. In
addition we hypothesize that patients receiving a
heparin-bonded endograft show better quality of life at
30-days compared to patients who were surgically
treated.
Sample size calculation
The assumption has been made that the heparin-bonded
endoluminal bypass will have a similar cumulative pri-
mary patency at one year compared to the venous
bypass. For a non-inferiority trial with an effect size of
90% and a margin of 10%, 111 patients per group are
needed (alpha 5%, power 80%). The effect size of 90%
refers to an estimated patency rate at one year in the
surgical control arm.
The assumption has been made that the heparin-
bonded endoluminal bypass will have an increase in
QOL, as measured by a 10-point increase in the SF-36
score, at 30 days follow-up. With a standard deviation
of 20, 63 patients per group are needed (alpha 5%,
power 80%).
Setting
Patients will be recruited from the following centers:
Rijnstate Hospital, Arnhem; Isala Klinieken, Zwolle; Nij
Smellinghe Hospital, Drachten; Antonius Hospital,
Sneek; University Medical Center Groningen, Gronin-
gen, The Netherlands. In each of the participating cen-
ters, each surgeon performing the endovascular
procedure must have placed at least ten endoluminal
bypasses prior to treating patients who participate in the
SuperB trial to prevent a learning curve bias.
The total study duration will be 7 years; the recruit-
ment period will take 2 years and thereafter patients will
be evaluated yearly until 5 years post-procedure.
Primary endpoints
The primary endpoints of the study are the primary
patency at 1-year follow-up. In addition the quality of
life, using the RAND SF36 Questionnaire will be evalu-
ated as a primary endpoint.
Secondary endpoints
1. Secondary patency
2. Complications
3. Clinical improvement
4. Surgical and endovascular re-interventions
5. Target lesion revascularization
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ing, subgroup-analysis will be performed.
- Patients with disabling intermittent claudication
( R u t h e r f o r d3 )w i l lb ea n a l y z e ds e p a r a t e l yu s i n g
pain-free and maximal walking distance and the
Walking Impairment Questionnaire as additional
endpoints.
- Patients with ischemic rest pain and necrosis
(Rutherford 4-6) will be analyzed using major ampu-
tations as an endpoint.
Ethical considerations
A patient who meets the entry criteria is fully informed
about the trial and provided with a patient information
and consent form. Patients willing to participate in the
study are included after signing the informed consent
form. This study is conducted in accordance with the prin-
ciples of the Declaration of Helsinki and Good Clinical
Practice guidelines. The study is approved by the Medical
Ethics committee of Nijmegen (CMO 2010-089) and the
local institutional board of each participating center.
Safety and quality control
Data Safety Monitoring Board
The Data Safety Monitoring Board (DSMB) will review
safety and makes recommendations regarding the con-
duct of the study to the steering committee and to the
accredited Medical Ethical Board (METC) that approved
the study protocol. An interim safety analysis will be
performed at 1-year after initiation of the trail. This ana-
lysis will include at least 40 patients.
Adverse and severe adverse events
Adverse events (AE) are defined as any undesirable
experience occurring to a participant during the study,
whether or not considered related to the investigational
device. This definition includes events occurring during
hospital stay up to 30 days of follow-up. Underlying dis-
ease that was present at the time of enrollment is not
reported as an AE, but any increase in the severity of
the underlying disease will be reported as an AE. All
AEs will be monitored from the time of enrolment
through the 30-day follow-up visit. AEs will be recorded
on the case record forms (CRFs). A description of the
event, including the start date, end date, action taken,
and the outcome will be provided.
A severe adverse event (SAE) is any event leading to
death, major amputation or definitive graft failure.
Data on AEs will be reported to the DSMB and to the
accredited METC via “Toetsingonline” on the website of
the Central Committee on Research involving Human
Subjects (CCMO, ccmo.nl).
Inclusion criteria
· Patients over 18 years of age
· Informed consent
· De novo stenosis, re-stenosis (Peak Systolic Velo-
city (PSV) ratio > 2.5) or occlusion of the native
SFA, all > 10 cm in length
· Popliteal artery is patent at the upper margin of the
patella to the trifurcation
· Diameter of the native SFA and popliteal arteries
are 5.0 to 7.5 mm
· Rutherford category 3-6
· Indication for surgical bypass
· Distal runoff at least 1 crural vessel without signifi-
cant stenosis
· Resting ankle-brachial index (ABI) < 0.8 in the
study limb prior to procedure
Exclusion criteria
· Patient unsuitable for administration of contrast
agent
· Pregnancy
· Dementia or altered mental status that would pro-
hibit giving conscious informed consent
· Need for adjunctive major surgical or vascular pro-
cedures within 1 month
· Untreated flow-limiting aorto-iliac occlusive disease
· Unsuccessful ipsilateral percutaneous vascular pro-
cedure to treat inflow disease just prior to
enrollment
· Previous ipsilateral bypass surgery or stent-
placement
· Femoral or popliteal aneurysm of target vessel
· Non-atherosclerotic disease resulting in occlusion
(e.g. embolism, Buerger’s disease, vasculitis)
· Severe medical co morbidities (untreated coronary
artery disease/congestive heart failure, severe chronic
obstructive pulmonary disease, metastatic malignan-
cies, dementia, etc.) or other medical condition that
would preclude compliance with the study protocol
· Major distal amputation (above the trans metatar-
sal) in the study limb
· Any previously known coagulation disorder, includ-
ing hypercoagulability
· Contraindication to anticoagulation or antiplatelet
therapy
· Known allergies to stent or stent-graft components
· History of prior life-threatening reaction to contrast
agent
· Patients with known hypersensitivity to heparin,
including those patients who have had a previous
incidence of heparin-induced thrombocytopenia
(HIT) type II
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occur after enrollment of the patient
Recruitment
Patients with symptomatic peripheral arterial disease of
the superficial femoral artery with a Rutherford category
3-6 [15] may be included in the study and will be
recruited among the 5 participating centers.
Randomization
Randomization will be performed during the out patient
department visit in which the patient is included. The
including physician will call the telephone number pro-
vided by the principle investigator. The person answer-
ing the phone will draw an envelope from a box of plain
white envelopes containing the randomization choice.
The envelopes are divided in batches of 20 and rando-
mization is stratified by center.
Imaging
Ultrasound imaging screens all patients included in the
study. Additionally, computed tomography angiography
(CTA) or magnetic resonance angiography (MRA) will
be performed. These imaging studies will be performed
according to the local protocol of the participating cen-
ters. The lesions in the SFA will be categorized accord-
ing to the Trans Atlantic Intersociety Consensus
(TASC)-II criteria. Type B, C, and D lesions may be
included.
Treatment details
Endovascular technique
Antibiotic prophylaxis is administered. Preferably a per-
cutaneous technique is used, but in case of a flush
occlusion or a diseased common femoral artery, an
open approach is allowed. The SFA may be approached
in a contralateral retrograde or an ipsilateral antegrade
fashion. When there is a concomitant lesion in the com-
mon or profunda femoral artery an endarterectomy may
be performed followed by the endoluminal bypass.
Heparin (5000 I.U.) is administered. The diseased seg-
ment of the SFA is passed, either endoluminal or sub-
intimal and a re-entry is created distally. The segment is
pre-dilated with a regular angioplasty balloon and the
endografts are positioned fr o md i s t a lt op r o x i m a lw i t h -
out or with minimal or no oversizing. The entire dis-
eased segment is covered with the stentgrafts and the
stentgrafts are post dilated with an angioplasty balloon
with the same size as the stent graft. Control angiogra-
phy is performed routinely and the access is closed
using a closure device, according to local protocols.
The used stent graft is the heparin-bonded Viabahn
Endoprothesis (W.L. Gore & associates, Flagstaff, AZ),
which is a self-expanding helical nitinol stent covered
with a heparin-bonded thin polytetrafluorethylene
(ePTFE) tube. The size of the stentgraft should be at
least 6 mm.
Post procedurally, all patients will be treated with
acetylsalicylic acid 80 mg and clopidogrel 75 mg for the
first year unless oral anticoagulation is indicated for
other reasons. After 1 year patients may be switched to
1 thrombocyt aggregation inhibitor. All patients receive
statin treatment, started before the intervention.
Open surgical technique
The surgical femoropopliteal bypass is performed
according to local protocols. Preferably the greater
saphenous vein is used as conduit in all patients. The
used vein has a diameter of at least 3.5 mm. Pre-opera-
tive vein mapping may be performed, but is not obliga-
tory. When the great saphenous vein is unavailable or
unsuitable a prosthetic graft may be used. When a pros-
thetic conduit is used the participating surgeon will
explicit this choice. All patients will be included in the
intention-to-treat analysis.
Post procedurally, all patients will be treated with
acetylsalicylic acid 80 mg and clopidogrel 75 mg for the
first year unless oral anticoagulation is indicated for
other reasons. After 1 year patients may be switched to
one thrombocyt aggregation inhibitor. All patients
receive statin treatment, started before the intervention.
Follow-up
Follow-up is planned at 1, 3, and 6 months. Afterwards
patients will be seen each 6 months until 2 years. From
2 to 5 years patients will be evaluated annually. Duplex
ultrasound imaging, ankle-brachial indices, and QOL
scores will be measured at all above mentioned time
points. All primary and secondary endpoint are regis-
tered as defined in the study protocol.
QOL scores
￿ RAND-36 is a multidimensional measurement of
health. This will also be used in both groups
￿ WIQ (Walking Impairment Questionnaire) is espe-
cially designed for patients with claudication, and
will only be used in patients treated for claudication.
These scores are taken prior to the intervention and at
defined times afterwards (i. e .1d a y ,1w e e k ,1m o n t h ,
etc).
Data collection
Data will be collected at the recruitment centre by
means of case report forms (CRF’s). The copies of the
CRF forms will be sent to the coordinating center (Rijn-
state Hospital) where all data will be entered in the
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monitor. The participating centers will be informed
about the current status of recruitment and adverse
events via a newsletter every 3 months. Additionally,
there will be regular contact between the principle
investigator and the contact persons from the participat-
ing centers.
Statistical analyses
Data concerning the 1, 2, and 5 year follow-up will be
analyzed for both study groups on an intention-to-treat
and a per-protocol manner by student t-test (normal
distribution) of Mann Whitney U-test (skewed distribu-
tion). Corrections will be made for study centre. Addi-
tionally, in case of sufficient numbers, the data will be
analyzed for different TASC II categories; otherwise the
analyses will be additionally adjusted for TASC II cate-
gories. Patency rates will be presented as Kaplan Meier
curves including censoring.
Publication of data
Data will be published after a follow-up period of 1, 2,
and 5 years, regardless of the outcome of the study under
the responsibility of dr. MMPJ Reijnen. Co-authorship
will be assigned according to the ‘ Uniform Requirements
for Manuscripts Submitted to Biomedical Journals: Writ-
ing and Editing for Biomedical Publication’ of the Inter-
national Committee of Medical Journal Editors.
Definitions
￿ Procedural success:
○ Endovascular - Successful vascular access,
exact deployment of the device and completion
of the endovascular procedure and immediate
morphological effect (< 30% residual stenosis)
○ Surgical - Successful access, completion of sur-
gical procedure and clinically assessed immediate
improvement
￿ Primary patency: The absence of occlusion or flow-
limiting stenosis (PSV ratio > 2.5) of the treated seg-
ment of the artery including 1 cm proximal and dis-
tal of the anastomosis, as documented by accepted
imaging techniques, particularly arteriography or
duplex ultrasonography, or direct observation at
operation or postmortem.
￿ Primary assisted patency: When a secondary endo-
vascular or open procedure is performed to prevent
failure, i.e. in a flow reducing stenosis (PSV ratio >
2.5), in a still-patent segment of the stent graft or
bypass, including the anastomoses.
￿ Secondary patency: When a thrombolytic or surgi-
cal treatment has been performed for graft or stent
graft occlusion in an afterwards patent vessel.
￿ Target lesion revascularization: Repeat percuta-
neous or surgical revascularization driven by clinical
state in the presence of a flow reducing stenosis or
occlusion in the treated segment of the artery includ-
ing 1 cm proximal and distal of the anastomosis.
￿ Type B lesion SFA according to TASC II criteria:
○ Multiple lesions (stenosis or occlusions), each
≤ 5c m
○ Single stenosis or occlusions ≤ 15 cm (not
involving infragenuale popliteal segment)
○ Heavily calcified occlusion ≤ 5 cm in length
○ Single popliteal stenosis
￿ Type C lesion SFA according to TASC II criteria:
○ Multiple stenosis or occlusions totaling > 15
cm with or without heavy calcification
○ Recurrent stenosis or occlusions that need
treatment after 2 endovascular interventions
￿ Type D lesion SFA according to TASC II criteria:
○ Chronic total occlusions of CFA or SFA (> 20
cm, involving the popliteal artery)
○ Chronic total occlusions of popliteal artery and
proximal trifurcation arteries
￿ Minor amputation: Below the ankle amputation,
planned or unplanned.
￿ Major amputation: Above the ankle amputation,
planned or unplanned
￿ Clinical improvement: Improved Rutherford classi-
fication compared to baseline.
￿ Intermediate lesion: Occlusion or stenosis > 10 cm
length
￿ Flow-reducing (re-)stenosis: A stenosis with a PSV
ratio of more than 2.5 as measured by duplex, or a >
50% (re-)stenosis on angiography, MRA or CTA.
￿ Graft failure: Definitive occlusion of the bypass
with unsuccessful thrombolytic or surgical treatment
￿ Re-intervention: Secondary percutaneous or surgi-
cal intervention of the bypass.
￿ Seroma - Non-infected fluid accumulation under
the wound
￿ Hematoma - Accumulation of blood postopera-
tively in the operated area.
￿ Re-bleed - Accumulation of blood postoperatively
requiring operative treatment.
￿ Abscess - Accumulation of pus in the operated area.
￿ Infected wound - Red, swollen, but closed wound,
not requiring surgical drainage.
￿ Open wound - Non infected wound leaking fluid.
￿ Loss of sensibility - Postoperative clinical loss of
sensibility of the skin in the operated leg.
￿ Femoral nerve damage - Clinical femoral nerve
damage.
￿ Graft infection - Proven graft infection requiring
long term use of antibiotics or graft removal.
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operated leg.
￿ Serious adverse event (SAE): An adverse event that
leads to death or serious deterioration in the health
of the subject, defined as death, definite failure of
graft/bypass or major amputation in the treated leg
Discussion
The aim of the present randomized trial is two-fold.
First, it aims to compare patency rates of the endolum-
inal bypass, combined with the heparin-bonded technol-
ogy, with the current gold standard, the venous femoro-
popliteal bypass, the current gold standard. Second, it
aims to demonstrate that an endovascular approach is
associated with fewer complications and thus an
improved quality of life. In order to have sufficient
power, the trial was designed using a non-inferiority
principle.
Data analysis will be performed in both an intention-
to-treat as a per-protocol manner. The first will be per-
formed to compare the endoluminal bypass with com-
mon surgical practice, namely that some patients will
not have a vein usable for the bypass and that some
endoluminal procedures will be converted to open sur-
gery. The per-protocol analysis will give information
about the performance of the endoluminal bypass itself.
There are several differences between the SuperB trial
and previously published randomized trials [9,16]. The
SuperB trial is the first trial using a heparin-bonded
endograft and the inclusion criteria are chosen much
broader since hybrid procedures, such as a reconstruc-
tion of the common femoral artery, are allowed. More-
over, the anti-platelet regime and the use of statins are
standardized. The wide inclusion criteria are chosen
because they mimic common surgical practice and
thereby they reduce the risk on inclusion problems as
was the case in the Scandinavian trial [16].
With the introduction of the heparin-bonded technol-
ogy in the endograft the design of the stent has also
been changed. The proximal edge of the endograft has
no longer a straight, but a contoured edge (Figure 1).
This adaptation will reduce infolding in case of oversiz-
ing, thereby maintaining laminar blood flow and pre-
venting intimal hyperplasia and thus edges stenosis. The
expected effect of the new endograft may therefore not
only be attributed heparin-bonding technology.
The SuperB trial hypothesizes that the treatment of
the long lesion of the SFA with a heparin-bonded endo-
graft will show equal patency rates compared to the sur-
gical bypass, but a better quality of life for treatment
with the heparin-bonded endograft is expected, related
to a reduced morbidity. Therefore, patients will be asked
to fill out the RAND 36 questionnaire before treatment
and at each visit during follow-up. Patients with inter-
mittent claudication additionally will be asked to fill out
the Walking Impairment Questionnaire at the same vis-
its. Trials on endoluminal bypass including quality of
life scores have not been performed, to date.
In conclusion, the SuperB trial is a multicentre rando-
mized controlled trial designed to show equality in
patency rates of the heparin-bonded endograft com-
pared to the surgical bypass for treatment of longer
lesions of the SFA, but to show better quality of life
using the heparin bonded-endograft compared to surgi-
cally treatment, related to a reduction in complications.
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Figure 1 The Viabahn endograft (W.L. Gore, Flagstaff, AZ, USA)
with a contoured proximal edge.
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